After examining a 1999 agreement between Barr Laboratories, Inc., and AstraZeneca PLC to buoy the price of the breast cancer drug tamoxifen, 17 consumer groups challenged its legality, and filed suit in five state courts and in the Eastern District of New York. The plaintiffs have requested class action status.
In 1992 Barr won the right to produce a generic form of tamoxifen. Zeneca Group PLC, which merged with Astra AB in 1999, paid Barr $21 million to sell Zeneca’s brand name tamoxifen, Nolvadex, and not to produce a generic.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
